• Sunday, Feb 05, 2023
  • Last Update : 10:24 am

India: No blood clot risk from Covishield, Covaxin

  • Published at 10:10 am March 23rd, 2021
Vaccine Bangladesh DMC
File Photo: A nurse fills a syringe with the Oxford-AstraZeneca's Covishield vaccine at the Dhaka Medical College Hospital vaccination centre in Dhaka, Bangladesh, February 9, 2021 Reuters

Serum Institute of India's Covishield has been developed in partnership with the Oxford University and AstraZeneca

A top Indian government committee has concluded on Tuesday that there is no increased risk of blood clotting following vaccinations with Covishield and Covaxin so far. 

The committee analyzed over 400 major adverse reactions during the government’s ongoing vaccination drive of priority groups in the country before submitting its findings, as per a top government official involved in the process, Indian Express reported.

“These cases have been analyzed and there is no unusual bleeding or clotting manifestations either with Covishield or Covaxin,” said Dr N K Arora, executive director of the INCLEN Trust and an advisor to the National Adverse Events Following Immunization (AEFI) Committee looking into this issue.

Of 412 cases of severe AEFI and serious AEFI, including hospitalizations and deaths, reported as of March 13, there is “no abnormal increase” in issues of clotting and bleeding either, he said.

According to Dr Arora the situation will continue to be monitored. A system is in the works to ensure a faster turnaround time between the time that a serious AEFI is reported by states and the Centre and the results of the investigations into them, as per him. 

This includes making the delivery of laboratory and post-mortem reports for each AEFI “much faster,” he said.

“We are (trying to see) that, within two or three weeks, the results should be available for each AEFI. It will be almost real-time,” Dr Arora told The Indian Express.

India’s decision to review serious and severe AEFIs for this issue follows concerns raised in other countries over this risk with the University of Oxford-AstraZeneca vaccine, on which Covishield is based.

50
Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail